Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAZE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Table of Contents As filed with the Securities and Exchange Commission on October 17, 2025. Jason Coloma, Ph.D. Chief Executive Officer 171 Oyster Point Blvd., Suite 300 South San Francisco, California ...

Core Viewpoint - The merger between Compass and Anywhere Real Estate will create a combined company valued at approximately $10 billion, significantly expanding Compass' market presence and agent network [1][4]. Company Overview - Compass is acquiring Anywhere Real Estate in an all-stock transaction, which will include major brands like Century 21 and Coldwell Banker under its umbrella [1][3]. - Anywhere Real Estate operates several well-known brokerage brands and also provides relocation, title, and settlement services [3]. Financial Impact - The merger is expected to increase Compass' agent network from about 40,000 to approximately 340,000, enhancing its market share to around 18% [4]. - Compass anticipates adding over $1 billion in revenue from Anywhere's escrow, title, and other businesses, which will help lower costs and improve cash flow [4]. Market Reaction - Following the announcement, shares of Anywhere Real Estate surged over 48%, while Compass shares fell by about 16% [2]. Deal Structure - Under the terms of the merger, Anywhere shareholders will receive approximately 1.4 shares of Compass, valuing Anywhere's shares at $13.01 each, representing an 84% premium over its previous closing price [7].

Core Viewpoint - Maze Therapeutics has successfully entered into an oversubscribed private placement agreement, raising approximately $150 million to advance its clinical programs and research initiatives [1][4]. Group 1: Private Placement Details - The private placement consists of 4,000,002 shares of common stock priced at $16.25 per share, along with 5,231,090 pre-funded warrants priced at $16.249 each [3]. - The transaction is expected to close on September 12, 2025, pending customary closing conditions [4]. - The placement has attracted both new and existing investors, including notable firms such as Frazier Life Sciences and Janus Henderson Investors [2]. Group 2: Use of Proceeds - Proceeds from the private placement will be utilized to further the development of MZE829 for APOL1-mediated kidney disease, initiate Phase 2 trials for MZE782 targeting phenylketonuria and chronic kidney disease, and support ongoing research and development efforts [4]. - Additional funds will be allocated for working capital and general corporate purposes [4]. Group 3: Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [8]. - The company's lead candidates include MZE829, an APOL1 inhibitor in Phase 2 development, and MZE782, a SLC6A19 inhibitor also advancing to Phase 2 [8].

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved record revenue of $2.06 billion, a 21.1% increase year-over-year, marking the highest quarterly revenue in its history [20][24] - Adjusted EBITDA reached $126 million, up 63% from $77 million in the same quarter last year, also a record high [5][24] - GAAP net income was $39.4 million, a 90% increase from $20.7 million a year ago, representing another record [24] - Free cash flow improved to $68 million from $40.4 million in Q2 2024, setting a new record for quarterly free cash flow [24] Business Line Data and Key Metrics Changes - Total transactions increased by 20.9%, with organic transactions up 6.3%, significantly outperforming the overall market where transactions declined by 0.9% [5][20] - Title and escrow revenue reached an all-time high, with attach rates for the title function nearing 75% for users of the one-click title feature [9][10] - The company successfully recruited 832 gross principal agents, a 53% increase year-over-year, marking the best recruiting quarter in its history [6][20] Market Data and Key Metrics Changes - Market share increased to 6.09%, up 96 basis points year-over-year and 8 basis points from Q1 [21] - Gross transaction value was $78.3 billion, reflecting a 20.3% increase from the previous year [21] Company Strategy and Development Direction - The company aims to manage operating expenses prudently, recruit and retain agents, build a productive platform, pursue accretive M&A, and grow high-margin businesses [13][27] - The company is focusing on leveraging AI to enhance its platform, aiming for a seamless integration of tools for agents [14][15] - The M&A pipeline is larger than ever, indicating strong demand for the company's services even in a challenging housing market [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to outperform competitors, particularly in a slowing housing market [8][10] - The management highlighted the importance of advocating for agents and providing them with more choices, contrasting with the control exerted by portals and MLSs [7][39] - The company anticipates continued growth in revenue and adjusted EBITDA, with a focus on maintaining operational efficiencies [26][27] Other Important Information - The company has achieved over $600 million in operating expense savings over the last three years, with a disciplined growth rate of 3% to 4% [12][27] - The CFO, Kalani Rielitz, announced his departure, with Scott Wallers being promoted to CFO [17][19] Q&A Session Summary Question: Thoughts on the $50 million benefit for next year - Management indicated that the $50 million benefit is expected to be a run rate savings, improving profitability and remaining sustainable over time [34][36] Question: Industry shifts and future operations - Management noted a tug-of-war in the industry between choice and control, emphasizing the need for sellers to have more choices in marketing their homes [38][39] Question: Changes in execution due to industry actions - Management confirmed that demand remains high and that the private exclusives strategy has not changed significantly, with agents gaining market share [49][50] Question: Appetite for acquisitions - Management expressed confidence in their capital position and indicated a strong interest in pursuing acquisitions, driven by the current industry environment [56][57] Question: Feedback on platform engagement and agent dashboard - Management reported strong feedback on the Compass One dashboard, noting that it is transforming agents' workflows and increasing transparency for clients [65][66] Question: Update on macro conditions in July - Management observed healthy trends in July, with pending contracts up 5% year-over-year, reflecting delayed demand from the spring market [93][94]

Table of Contents As filed with the Securities and Exchange Commission on January 29, 2025 Registration No. 333-284164 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAZE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2836 82-2635018 (I.R.S. Emplo ...

Table of Contents As filed with the Securities and Exchange Commission on January 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAZE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 82-2635018 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...